Gastrointestinal Therapeutics Market, By Medication Type (Branded and Generics), By Drug Type, By Dosage Form, By Application, By Distribution Channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4158
|
Published Date
July 2025
|
Pages
284
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Gastrointestinal Therapeutics Market size was valued at US$ 40,209.11 Million in 2024, expanding at a CAGR of 5.50% from 2025 to 2032.
The Gastrointestinal Therapeutics Market encompasses the development, production, and distribution of medications designed to treat disorders of the digestive system. This includes a wide range of conditions such as Crohn’s disease, ulcerative colitis, gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), and various gastrointestinal (GI) infections.
The market offers a diverse portfolio of treatments, including antacids, biologics, anti-diarrheal agents, proton pump inhibitors (PPIs), laxatives, and antibiotics—available in both oral and injectable formulations. Demand for gastrointestinal therapeutics continues to rise, driven by increasing prevalence of GI diseases, lifestyle-related digestive issues, and advancements in targeted therapies and biologic drugs. The market includes both branded and generic medications and is primarily distributed through hospitals, retail pharmacies, and online platforms. As research and innovation accelerate, particularly in the areas of biologics and personalized medicine, the gastrointestinal therapeutics market is poised for sustained growth.
Gastrointestinal Therapeutics Market- Market Dynamics
Advancements in Biologics Drive Greater Therapeutic Effectiveness and Adoption
Recent advancements in biologic therapies have significantly transformed the treatment landscape for gastrointestinal (GI) disorders by providing more targeted, effective, and personalized treatment options. Unlike traditional drugs, biologics work by precisely modulating the immune system, helping to control inflammation and manage chronic symptoms more effectively. A notable example is AbbVie\'s Humira (adalimumab), a widely used biologic for conditions such as Crohn’s disease and ulcerative colitis. Its targeted mechanism has led to marked improvements in patient outcomes, setting a benchmark for biologic efficacy in GI care. The emergence of biosimilars—affordable versions of biologic drugs with comparable safety and efficacy—has further accelerated the adoption of these therapies by increasing accessibility, particularly in cost-sensitive regions.
For instance,
March 2024: Pfizer expanded its footprint in the GI therapeutics market by launching biosimilar versions of popular biologics. These biosimilars offer similar clinical effectiveness at a reduced cost, enabling wider access to advanced therapies across diverse patient populations.
September 2023: Johnson & Johnson introduced innovative biologic treatments for inflammatory bowel diseases (IBD). These new therapies target specific immune pathways to more effectively reduce inflammation, offering improved options for long-term disease management and better patient outcomes.
The combination of ongoing innovation and increased affordability through biosimilars is expected to fuel significant growth in the gastrointestinal therapeutics market while enhancing treatment efficacy and patient quality of life.
Gastrointestinal Therapeutics Market- Segmentation Analysis:
The global gastrointestinal therapeutics market is segmented by medication type into branded and generic categories, with the branded segment currently dominating the market. This dominance is largely driven by strong physician preference for well-established, clinically validated medications, which are often supported by aggressive marketing strategies and high brand recognition. Branded drugs are frequently the first choice for treating complex gastrointestinal (GI) conditions such as Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS) due to their proven efficacy and innovative formulations. Furthermore, patent protections and regulatory exclusivity have restricted the widespread entry of generics in several therapeutic areas, particularly in developed markets where the demand for advanced and specialized treatments is high. According to the World Health Organization (WHO), noncommunicable diseases—including digestive system disorders—are rising globally, with increasing investment and focus on innovation in chronic condition therapies, thus supporting the continued dominance of branded medications in the GI market.
Based on application, the market is segmented into Crohn’s disease, gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), ulcerative colitis, and others, with GERD emerging as the leading application segment. This is primarily due to its high global prevalence, particularly in North America and Europe, and its chronic nature, which often necessitates ongoing or lifelong pharmaceutical intervention. The widespread and prolonged use of proton pump inhibitors (PPIs) and H2 receptor antagonists, coupled with increased diagnosis rates due to lifestyle factors such as obesity, unhealthy diets, and elevated stress levels, significantly boosts demand for GERD treatments. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 20% of the U.S. population experiences GERD symptoms regularly. Moreover, pharmaceutical companies continue to invest in R&D pipelines and product innovations tailored to GERD, further solidifying its dominant position within the gastrointestinal therapeutics market.
Gastrointestinal Therapeutics Market- Geographical Insights
North America Leads the Global Gastrointestinal Therapeutics Market in 2024
North America leads the global gastrointestinal therapeutics market, holding the largest market share due to its advanced healthcare infrastructure, high per capita healthcare spending, and strong presence of major pharmaceutical manufacturers. The region bears a substantial burden of gastrointestinal disorders such as GERD, IBS, and Crohn’s disease, which fuels consistent demand for effective and innovative treatment options. The United States, in particular, plays a pivotal role in driving regional growth, supported by robust R&D investments, favorable regulatory frameworks, and rapid adoption of new therapies. High levels of disease awareness, early and accurate diagnostics, and supportive reimbursement policies further contribute to the region’s market dominance. According to data from the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending reached $4.5 trillion in 2022, representing nearly 18% of the GDP, a portion of which is increasingly allocated toward managing chronic gastrointestinal conditions and funding pharmaceutical innovation.
Asia-Pacific Projected to Record the Highest CAGR in the Gastrointestinal Therapeutics Market in 2024
In contrast, the Asia-Pacific region is emerging as the fastest-growing market for gastrointestinal therapeutics, driven by its large and aging population and the rising prevalence of GI disorders. Factors such as urbanization, changing dietary habits, and sedentary lifestyles have led to a surge in conditions like GERD, IBS, and ulcerative colitis. Countries such as China, India, and South Korea are experiencing significant growth in healthcare investments and policy-driven efforts to expand access to medical care. Pharmaceutical companies are increasingly targeting this region for its untapped market potential and growing demand for affordable, high-quality treatments. In addition, awareness campaigns and enhancements in healthcare infrastructure are accelerating early diagnosis and treatment uptake. According to the World Health Organization (WHO), noncommunicable diseases—including digestive system disorders—are responsible for over 70% of global deaths, and Asia accounts for a substantial share due to its population size. In response, several governments across the region are intensifying efforts to strengthen healthcare systems, which is expected to further boost the gastrointestinal therapeutics market.
Gastrointestinal Therapeutics Market- Competitive Landscape:
The gastrointestinal therapeutics market is highly competitive, characterized by the presence of both global pharmaceutical giants and emerging regional players. Leading companies such as AbbVie Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Pfizer Inc., and AstraZeneca maintain dominant positions through robust product portfolios targeting key GI disorders, including Crohn’s disease, ulcerative colitis, gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS).
These major players focus on strategic collaborations, mergers and acquisitions, and extensive research and development (R&D) to enhance their therapeutic offerings and sustain market leadership. Simultaneously, emerging biotech firms are entering the market with innovative biologics and small molecules, aiming to deliver improved safety and efficacy profiles. The growing availability of biosimilars and generic drugs is intensifying price competition, particularly in developing markets. To stay competitive, companies are investing heavily in geographic expansion, regulatory approvals, and the development of advanced drug delivery systems. Overall, the competitive landscape is being shaped by innovation, a strong product pipeline, and global market expansion.
Recent Developments:
- February 2025: Zydus Lifesciences received U.S. FDA approval for its Ibuprofen and Famotidine tablets, formulated to treat rheumatoid arthritis and osteoarthritis while reducing the risk of upper GI ulcers. This approval strengthens Zydus’s gastrointestinal portfolio, particularly in addressing the rising incidence of peptic ulcers.
- April 2025: Allergan plc completed the acquisition of Viral Burn, a privately held biotech firm focused on novel GI therapeutics. The acquisition adds VB-201, a first-in-class, oral, non-systemic antiviral treatment for norovirus gastroenteritis, to Allergan’s development pipeline—expanding its reach into infectious GI diseases.
- April 2021: Teva Pharmaceuticals USA launched its generic version of Casana (mesalamine) 1000 mg suppository for adults with active ulcerative proctitis in the U.S. This cost-effective alternative increases treatment accessibility and strengthens Teva’s position in the GI market, capitalizing on the rising prevalence of ulcerative colitis.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca Plc
- Bayer AG
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- Boston Scientific Corp.
- Cipla
- Eisai Co. Ltd.
- Eli Lilly and Co.
- Evoke Pharma Inc.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Merck and Co. Inc.
- Novartis AG
- Olympus Corp.
- Ovesco Endoscopy AG
- Pfizer Inc.
- Salix Pharmaceuticals Inc.
- Takeda Pharmaceutical Co. Ltd.
- UCB SA
- Others
GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY MEDICATION TYPE- MARKET ANALYSIS, 2019 - 2032
- Branded
- Generics
GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032
- Antacids
- Antiemetics
- Antidiarrheals
- Antiulcer agents
- Antibiotics
- Biologics/ biosimilars
- Laxatives
- Proton pump inhibitors (PPIs)
- Other drug types
GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032
- Oral
- Parenteral
GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
- Crohn\'s disease
- Gastroesophageal reflux disease (GERD)
- Irritable Bowel Syndrome (IBS)
- Ulcerative colitis
- Others
GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Gastrointestinal Therapeutics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Gastrointestinal Therapeutics Market Snippet by Medication Type
2.1.2. Gastrointestinal Therapeutics Market Snippet by Drug Type
2.1.3. Gastrointestinal Therapeutics Market Snippet by Dosage Form
2.1.4. Gastrointestinal Therapeutics Market Snippet by Application
2.1.5. Gastrointestinal Therapeutics Market Snippet by Distribution Channel
2.1.6. Gastrointestinal Therapeutics Market Snippet by Country
2.1.7. Gastrointestinal Therapeutics Market Snippet by Region
2.2. Competitive Insights
3. Gastrointestinal Therapeutics Key Market Trends
3.1. Gastrointestinal Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Gastrointestinal Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Gastrointestinal Therapeutics Market Opportunities
3.4. Gastrointestinal Therapeutics Market Future Trends
4. Gastrointestinal Therapeutics Industry Study
4.1. PESTEL Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Gastrointestinal Therapeutics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Gastrointestinal Therapeutics Market Landscape
6.1. Gastrointestinal Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Gastrointestinal Therapeutics Market – By Medication Type
7.1. Overview
7.1.1. Segment Share Analysis, By Medication Type, 2024 & 2032 (%)
7.1.2. Branded
7.1.3. Generics
8. Gastrointestinal Therapeutics Market – By Drug Type
8.1. Overview
8.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
8.1.2. Antacids
8.1.3. Antiemetics
8.1.4. Antidiarrheals
8.1.5. Antiulcer agents
8.1.6. Antibiotics
8.1.7. Biologics/ biosimilars
8.1.8. Laxatives
8.1.9. Proton pump inhibitors (PPIs)
8.1.10. Other drug types
9. Gastrointestinal Therapeutics Market – By Dosage Form
9.1. Overview
9.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
9.1.2. Oral
9.1.3. Parenteral
10. Gastrointestinal Therapeutics Market – By Application
10.1. Overview
10.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
10.1.2. Crohn\'s disease
10.1.3. Gastroesophageal reflux disease (GERD)
10.1.4. Irritable Bowel Syndrome (IBS)
10.1.5. Ulcerative colitis
10.1.6. Others
11. Gastrointestinal Therapeutics Market – By Distribution Channel
11.1. Overview
11.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
11.1.2. Hospital pharmacies
11.1.3. Retail pharmacies
11.1.4. Online pharmacies
12. Gastrointestinal Therapeutics Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
12.2.1. Overview
12.2.2. Gastrointestinal Therapeutics Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4. North America Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.2.6. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Gastrointestinal Therapeutics Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.11.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Gastrointestinal Therapeutics Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.8. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.9.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.10.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.17. Rest of APAC
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.17.3. Rest of APAC Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.4.17.5. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.4.17.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Gastrointestinal Therapeutics Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.5.8. LATAM Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Gastrointestinal Therapeutics Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.15. Rest of MEA
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.15.3. Rest of MEA Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
12.6.15.5. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
12.6.15.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Gastrointestinal Therapeutics Industry
13.1. Competitive Benchmarking
13.1.1. Competitive Dashboard
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. Abbott Laboratories
13.2.2. AbbVie Inc.
13.2.3. AstraZeneca Plc
13.2.4. Bayer AG
13.2.5. Biogen Inc.
13.2.6. Boehringer Ingelheim International GmbH
13.2.7. Boston Scientific Corp.
13.2.8. Cipla
13.2.9. Eisai Co. Ltd.
13.2.10. Eli Lilly and Co.
13.2.11. Evoke Pharma Inc.
13.2.12. GlaxoSmithKline Plc
13.2.13. Johnson and Johnson Services Inc.
13.2.14. Merck and Co. Inc.
13.2.15. Novartis AG
13.2.16. Olympus Corp.
13.2.17. Ovesco Endoscopy AG
13.2.18. Pfizer Inc.
13.2.19. Salix Pharmaceuticals Inc.
13.2.20. Takeda Pharmaceutical Co. Ltd.
13.2.21. UCB SA
13.2.22. Others
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
